Company: BOLT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058632
Chunk: 30

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 30
---
 in total value or (ii) in the event such non-employee director is first appointed or elected during such annual period, $1,500,000 in total value, in each case calculating the value of any equity awards based on the grant date fair market value for financial reporting purposes. Consulting Agreement with Jakob Dupont, M.D. In April 2025, we entered into a Consulting Agreement with Dr. Dupont that will commence on May 1, 2025. Under this agreement, Dr. Dupont will provide consulting services to us as may be requested from time to time by our Chief Executive Officer. As compensation for these services, we will grant Dr. Dupont 20,000 stock options and pay Dr. Dupont an agreed-upon hourly rate, plus reasonable and necessary expenses, with total consulting compensation (including the grant date fair value of any equity awards) not to equal or exceed $120,000 in any rolling 12-month period.

<div align='center'>18

REPORT OF THE AUDITCOMMITTEE OF THE BOARD OF DIRECTORS</div>

The audit committee assists the Board in its oversight of the Company’s financial statements and reporting process, audit process and internal controls. The audit committee operates under a written charter adopted by the Board, which describes this and the other responsibilities of the audit committee. Management has the primary responsibility for the financial statements and the reporting process, including the systems of internal controls. Our independent registered public accounting firm is responsible for performing an independent audit of our consolidated financial statements in accordance with the auditing standards of the Public Company Accounting Oversight Board, or PCAOB, and to issue a report thereon.

The audit committee has reviewed and discussed the Company’s audited financial statements with management, which has primary responsibility for the financial statements. PricewaterhouseCoopers LLP, the Company’s independent registered public accounting firm for the year ended December 31, 2024, is responsible for expressing an opinion on the conformity of the Company’s audited financial statements with generally accepted accounting principles. The audit committee has discussed with PricewaterhouseCoopers LLP the matters required to be discussed by the applicable requirements of the PCAOB and SEC. The audit committee has received and reviewed the written disclosures and the letter from PricewaterhouseCoopers LLP required by applicable requirements of the PCAOB regarding PricewaterhouseCoopers LLP’s communications with the audit committee concerning independence, and has discussed with PricewaterhouseCoopers LLP its independence.

Based on the review and discussions referred to above